AU Patent
AU2014259756B2 — Compositions and methods for modulating apolipoprotein C-III expression
Assigned to Ionis Pharmaceuticals Inc · Expires 2017-02-23 · 9y expired
What this patent protects
Provided herein are oligomeric compounds with conjugate groups targeting apoplipoprotein C-III (ApoClll). In certain embodiments, the ApoClll targeting oligomeric compounds are conjugated to
USPTO Abstract
Provided herein are oligomeric compounds with conjugate groups targeting apoplipoprotein C-III (ApoClll). In certain embodiments, the ApoClll targeting oligomeric compounds are conjugated to
Drugs covered by this patent
Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.
Track this patent
Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.